The NIH intramural research program has shifted all non-mission-critical laboratory operations to a maintenance phase in order to promote physical distancing and diminished transmission risk of COVID-19. Effective Monday, March 23, 2020, only mission-critical functions within NIH research laboratories will be supported.

Funding

On this page

New Funding Opportunities Funded Projects Closed Funding Opportunities

New Funding Opportunities

RADxSM Radical (RADx-rad)

Notice: Emergency Awards: RADx-RAD Multimodal COVID-19 surveillance methods for high risk clustered populations (R01 Clinical Trial Optional)
Notice Number: RFA-OD-20-016​
Post Date: August 6, 2020
Application Due Date(s): September 30, 2020
Expiration Date: October 1, 2020

Notice: Emergency Awards: RADx-rad Data Coordination Center (DCC) (U24 Clinical Trial Not Allowed)
Notice Number: RFA-OD-20-019
Post Date: August 6, 2020
Application Due Date(s): September 30, 2020
Expiration Date: October 1, 2020

Notice: Emergency Awards: RADx-rad Predicting Viral-Associated Inflammatory Disease Severity in Children with Laboratory Diagnostics and Artificial Intelligence (PreVAIL kIds) (R61/R33 Clinical Trial Optional)
Notice Number: RFA-OD-20-023
Post Date: August 6, 2020
Application Due Date(s): September 30, 2020
Expiration Date: October 1, 2020

Notice: Notice of Intent to Publish Funding Opportunity Announcements for the RADx-rad Initiative
Notice Number: NOT-OD-20-144
Post Date: July 10, 2020

Funded Projects

Project Title: Rapid Manufacturing Scale-up for Compact Point-of-Care EUA SARS-CoV-2 RT-PCR Test
Awardee: Mesa Biotech, Inc.
Description: This test employs a hand-held RT-PCR device and a compact, single-use cartridge that detects viral RNA at the point of care. Results can be read from the removable cartridge in 30 minutes.
Budget: $18,536,704
Additional Information: RADx Tech/ATP Phase 2 Awards

Project Title: Talis-One/Talis HT: Highly Scalable SARS-CoV-2 RNA Detection in Minutes, from POC to Hundred-per-Hour Throughput
Awardee: Talis Biomedical Corp.
Description: This point of care test is a multiplexed cartridge used with the compact Talis One instrument. The test detects SARS-CoV-2 through isothermal amplification of viral RNA and an optical detection system, returning a result in under 30 minutes.
Budget: $25,400,000
Additional Information: RADx Tech/ATP Phase 2 Awards

Project Title: Manufacturing Capacity Scale-Up for Sofia SARS Antigen and Sofia Influenza A+B/SARS FIAs
Awardee: Quidel Corp.
Description: This test kit, a lateral flow immunoassay, is used with Sofia and Sofia 2 Analyzers in point of care settings, such as a doctor’s office or pharmacy. There are currently thousands of Quidel analyzers in place across the U.S. and HHS has identified this technology for nursing homes. The Analyzers give electronic results within 15 minutes.
Budget: $71,000,000
Additional Information: RADx Tech/ATP Phase 2 Awards

Project Title: Detection of SARS-CoV-2 with the CRISPR-based DETECTR platform
Awardee: Mammoth Biosciences
Description: This assay uses CRISPR technology, which provides a simpler workflow and significantly faster turnaround time compared to conventional laboratory PCR tests. This high-throughput solution can result in a multi-fold increase in testing capacity in commercial laboratories.
Budget: $23,081,269
Additional Information: RADx Tech/ATP Phase 2 Awards

Project Title: Scaling to Massive Throughput: 4.5 Million SARS-CoV-2 Tests per Day
Awardee: Fluidigm Corp.
Description: Each BioMark HD microfluidics platform has the capacity to process thousands of SARS-CoV-2 PCR tests per day with a primary focus on saliva samples. With many existing Fluidigm instruments in clinical and research labs throughout the U.S., scale up and deployment of their advanced integrated fluidic chips can provide tens to hundreds of thousands of new tests per day in fall 2020.
Budget: $36,834,000
Additional Information: RADx Tech/ATP Phase 2 Awards

Project Title: Reproducible clinical test system for 1 million daily SARS-CoV-2 tests using amplicon sequencing
Awardee: Helix OpCo, LLC
Description: Helix will ship standardized kits in bulk for the collection of nasal swabs to public health departments, health care systems, employers and other customers to collect tens of thousands of samples and processed within 24-48 hours using sophisticated automation processes and next generation sequencing technologies. Expected to process up to 50,000 samples/day by Sept. 2020 and 100,000/day by year’s end.
Budget: $33,421,500
Additional Information: RADx Tech/ATP Phase 2 Awards

Project Title: RADx-ATP Concentric: A High-Throughput Next Generation Sequencing-based Molecular Diagnostic for SARS-CoV-2
Awardee: Ginkgo Bioworks
Description: Ginkgo is scaling up by using significant automation and next-generation sequencing technologies to process tens of thousands of tests at once. Working with universities, schools, public or private companies, and local communities, they will provide end-to-end sample collection and report results within 24-48 hours. Expected to scale up to 50,000 tests/day in Sept. 2020 and 100,000/day by year’s end.
Budget: $40,473,832
Additional Information: RADx Tech/ATP Phase 2 Awards

Closed Funding Opportunities

RADxSM Underserved Populations (RADx-UP)

Notice: Emergency Awards: RADx-UP Coordination and Data Collection Center (CDCC) (U24 Clinical Trial Optional)
Notice Number: RFA-OD-20-013
Post Date: June 12, 2020
Application Due Date(s): August 7, 2020
Expiration Date: August 8, 2020
Additional Information:

Notice: Notice of Special Interest (NOSI): Limited Competition for Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
Notice Number: NOT-OD-20-121
Post Date: June 12, 2020
Application Due Date(s): August 7, 2020
Expiration Date: August 8, 2020
Additional Information:

Notice: Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
Notice Number: NOT-OD-20-120
Post Date: June 12, 2020
Application Due Date(s): August 7, 2020; September 8, 2020
Expiration Date: September 9, 2020
Additional Information:

Notice: Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations
Notice Number: NOT-OD-20-119
Post Date: June 12, 2020
Application Due Date(s): August 7, 2020; September 8, 2020
Expiration Date: September 9, 2020
Additional Information:

RADxSM Radical (RADx-rad)

Notice: Notice of Special Interest (NOSI): Availability of Emergency Competitive Revisions for Wastewater Surveillance Research for Public Health Response to Coronavirus Disease 2019 (COVID-19)
Notice Number: NOT-OD-20-159
Post Date: August 6, 2020
Application Due Date(s): August 21, 2020
Expiration Date: August 22, 2020

Notice: Availability of Emergency Competitive Revisions for Chemosensory Testing as a COVID-19 Screening Tool
Notice Number: NOT-OD-20-152
Post Date: August 6, 2020
Application Due Date(s): September 15, 2020
Expiration Date: September 16, 2020

Notice: Emergency Awards: Automatic Detection and Tracing of SARS-CoV-2 (U01 Clinical Trial Not Allowed)
Notice Number: RFA-OD-20-014​
Post Date: August 6, 2020
Application Due Date(s): September 15, 2020
Expiration Date: September 16, 2020

Notice: Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed)
Notice Number: RFA-OD-20-015
Post Date: August 6, 2020
Application Due Date(s): September 15, 2020
Expiration Date: September 16, 2020

Notice: Emergency Awards: Chemosensory Testing as a COVID-19 Screening Tool (U01 Clinical Trial Optional)
Notice Number: RFA-OD-20-022
Post Date: August 6, 2020
Application Due Date(s): September 15, 2020
Expiration Date: September 16, 2020

Notice: Emergency Awards RADx-RAD: Screening for COVID-19 by Electronic-Nose Technology (SCENT) (U18 Clinical Trial Not Allowed)
Notice Number: RFA-OD-20-017
Post Date: August 6, 2020
Application Due Date(s): September 18, 2020
Expiration Date: September 19, 2020

Notice: Emergency Awards: Exosome-based Non-traditional Technologies Towards Multi-Parametric and Integrated Approaches for SARS-CoV-2 (U18 Clinical Trial Not Allowed)
Notice Number: RFA-OD-20-018
Post Date: August 6, 2020
Application Due Date(s): September 18, 2020
Expiration Date: September 19, 2020

Notice: Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (R44 Clinical Trial Not Allowed)
Notice Number: RFA-OD-20-020
Post Date: August 6, 2020
Application Due Date(s): September 18, 2020
Expiration Date: September 19, 2020

Notice: Emergency Awards RADx-RAD: Novel Biosensing for Screening, Diagnosis and Monitoring of COVID-19 From Skin and The Oral Cavity (Fast-Track STTR Clinical Trial Not Allowed)
Notice Number: RFA-OD-20-021
Post Date: August 6, 2020
Application Due Date(s): September 18, 2020
Expiration Date: September 19, 2020

This page last reviewed on September 24, 2020